Indication
Besremi is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly.
Loading your page…
Loading your page…
Polycythemia Vera
Marketing Authorisation Holder: AOP Orphan Pharmaceuticals GmbH
EMA Authorisation: 15/02/2019
INN: ropeginterferon alfa-2b
AI Drug & Interaction Analysis
Free account required
Ask Osler about Besremi: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.